1-3 of 3
Sarah Mirjam Eckhoff, MD
Close
Sort by
Journal Articles

CRLF2 Rearrangement Is Not Associated with Activated mTOR Pathway in NOD/SCID/huALL Xenograft Mouse Model.

Md. Nabiul Hasan, MSc, Silvia Bresolin, PhD, Ilaria Bronzini, PhD, Chiara Palmi, PhD, Manon Queudeville, MD, Sarah Mirjam Eckhoff, MD, Luca Trentin, PhD, Giovanni Cazzaniga, PhD, Geertury te Kronnie, PhD, Klaus-Michael Debatin, MD, PhD, Lüder-Hinrich Meyer, MD
Journal: Blood
Blood (2012) 120 (21): 2518.
https://doi.org/10.1182/blood.V120.21.2518.2518
Published: 2012
Journal Articles

Hyperactivated mTOR Signaling Is a Characteristic Feature of High Risk Acute Lymphoblastic Leukemia and Can Be Effectively Targeted in a Preclinical NOD/SCID/huALL Xenograft Mouse Model

Md. Nabiul Hasan, MSc, Manon Queudeville, MD, Sarah Mirjam Eckhoff, MD, Manuel Herrmann, Simone Miller, Luca Trentin, PhD, Klaus-Michael Debatin, MD PhD, Lueder Hinrich Meyer, MD
Journal: Blood
Blood (2011) 118 (21): 2572.
https://doi.org/10.1182/blood.V118.21.2572.2572
Published: 2011
Journal Articles

High Risk Acute Lymphoblastic Leukemia with Rapid NOD/SCID Engraftment Is Characterized by High Protein Expression of CYCLIN B, Beta-CATENIN, ANNEXIN I and Decreased PKC Alpha Activation

Felix Seyfried, Benedetta Accordi, PhD, Manon Queudeville, MD, Sarah Mirjam Eckhoff, MD, Gloria Milani, Luisa Galla, Marco Giordan, PhD, Johann M Kraus, Giuseppe Basso, MD PhD, Hans Armin Kestler, PhD, Geertruy te Kronnie, PhD, Klaus-Michael Debatin, MD, PhD, Lueder Hinrich Meyer, MD
Journal: Blood
Blood (2011) 118 (21): 1457.
https://doi.org/10.1182/blood.V118.21.1457.1457
Published: 2011